09/30/22 8:00 AMAMEX : SYN clinical triallow floatSynthetic Biologics Announces Presentation at SIOP International Society of Pediatric Oncology on New Preclinical Data Supporting Evaluation of VCN-01 and Topotecan for the Treatment of Refractory RetinoblastomaSynthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treatRHEA-AIneutral
09/27/22 8:00 AMAMEX : SYN clinical triallow floatSynthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant RecipientsSynthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage companyRHEA-AIneutral
09/05/22 8:00 AMAMEX : SYN clinical triallow floatSynthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and NeckSynthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeuticsRHEA-AIneutral
08/11/22 8:00 AMAMEX : SYN earningslow floatSynthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results-Prioritizing the advancement of novel oncolytic adenovirus (OV) platform- -Cash balance as of August 1, 2022 of $53.5 million, including the additional $3 million in gross proceeds from convertible preferred financing extends funding for business operations into Q1 2024- -Conference call andRHEA-AIneutral
08/04/22 4:05 PMAMEX : SYN conferenceslow floatSynthetic Biologics to Participate in the BTIG Biotechnology Conference 2022Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that Company’s management will participate in one-on-one investorRHEA-AIneutral
08/04/22 8:00 AMAMEX : SYN conferencesearningslow floatSynthetic Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2022 Operational Highlights and Financial ResultsSynthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it plans to host a conference call on Thursday, August 11,RHEA-AIneutral
07/29/22 4:05 PMAMEX : SYN low floatSynthetic Biologics Announces $3 Million Private Placement of Convertible Preferred StockSynthetic Biologics, Inc.. (NYSE American: SYN) (“Synthetic Biologics” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced the private placement ofRHEA-AIneutral
07/15/22 8:00 AMAMEX : SYN low floatSynthetic Biologics Announces Reverse Stock SplitSynthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced today a reverse stock split of its issued and outstanding common stock,RHEA-AIneutral
05/16/22 8:00 AMAMEX : SYN earningslow floatSynthetic Biologics Reports First Quarter 2022 Operational Highlights and Financial Results-Encouraging data further supports the development of novel oncolytic adenovirus (OV) platform; Announced a peer-reviewed publication highlighting positive clinical data on VCN-01 and an upcoming oral presentation on VCN-11, a novel oncolytic adenovirus designed to evade neutralizing antibodies- -RHEA-AIneutral
05/10/22 8:00 AMAMEX : SYN clinical triallow floatSynthetic Biologics Reports Positive Safety Data on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical TrialSynthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas ofRHEA-AIneutral